The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer therapies and is the world’s largest gathering of the clinical oncology community. This year marks ...
MDM2 and MDMX are RING domain proteins that exert their oncogenic effects primarily by inhibiting the p53 tumour suppressor protein. Each protein is overexpressed in diverse tumour types by mechanisms ...
Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) ...
Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...
Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...
A study has identified a possible second-line treatment for melanoma patients. A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, PhD, and Ann ...
The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with ...
A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results